Oral Semaglutide Reviews Cardiovascular Risks in diabetes

The study enrolled 9,650 patients from 444 medical centers in 33 countries. Participants had type 2 diabetes along with atherosclerotic cardiovascular disease, chronic kidney disease, or both. The average age of participants was about 66 years, and 29% were women.
Patients were followed for about 47.5 months, allowing researchers to evaluate the long-term cardiovascular effects of the treatment, including oral semaglutide reviews.

Treatment Plan

These findings align with the latest oral semaglutide reviews that discuss its efficacy and safety in managing diabetes.

Participants were randomly assigned to receive oral semaglutide or a placebo, in addition to their regular medical treatments. To reduce side effects, the medication dose was gradually increased:

  • 3 mg daily for the first 4 weeks
  • 7 mg daily for the next 4 weeks
  • 14 mg daily as the maintenance dose

🟢 Patients continued their usual treatments such as:

  • Statins
  • Blood pressure medications
  • Other diabetes medications

Heart Failure in the Study Population

Around 23% of participants had heart failure at the start of the study. These patients had different types of heart failure, including:

  • Heart failure with preserved ejection fraction (HFpEF)
  • Heart failure with reduced ejection fraction (HFrEF)
  • Unclassified heart failure

Compared with others, patients with heart failure generally had:

  • Higher body mass index (BMI)
  • Higher HbA1c levels
  • Higher diastolic blood pressure

Cardiovascular and Heart Failure Results

The study showed that oral semaglutide reduced the risk of major heart failure-related events in patients who already had heart failure. The combined outcome included:

  • Hospitalization for heart failure
  • Urgent visits for worsening heart failure
  • Cardiovascular death

The largest benefit was seen in patients with HFpEF, where heart failure events were significantly lower compared with placebo. However, no clear benefit was observed in patients with HFrEF. In addition, oral semaglutide reduced major adverse cardiovascular events (MACE) such as:

  • Cardiovascular death
  • Heart attack
  • Stroke

These benefits were seen regardless of whether patients had heart failure at the beginning of the study.

What This Means for Clinical Practice

🔵 The results suggest that oral semaglutide offers cardiovascular protection in addition to improving blood sugar control.

🔵 Its benefits appear similar to those seen with injectable semaglutide, showing that the oral form is also effective.

🔵 Overall, the SOUL trial strengthens the role of oral semaglutide in managing high-risk patients with type 2 diabetes.

Pharmacist

Pharmacist, highly trained and knowledgeable healthcare professional who possesses extensive experience. With years of clinical practice and often specialized training in a particular field of medicine, can provide information regarding medical condition and diseases, medical research, and healthcare education.

Similar Posts